Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
13043.80 | 16,735 Cr | 93.42 | 10.34 | 0.09 | 12.09 | 14.48 | 7.07 | |
2016.25 | 16,507 Cr | 57.52 | 11.68 | 0.07 | 15.84 | 21.30 | 16.80 | |
912.70 | 14,539 Cr | 31.51 | 2.21 | 0.55 | 7.25 | 7.77 | 3.18 | |
320.10 | 3,413 Cr | 72.92 | 12.91 | 0.21 | 18.26 | 19.25 | 12.68 | |
371.00 | 3,388 Cr | 16.71 | 2.31 | 0.27 | 13.56 | 13.12 | 7.75 | |
335.25 | 3,151 Cr | 35.03 | 4.32 | 0.11 | 11.57 | 12.36 | 6.82 | |
213.35 | 2,631 Cr | 105.10 | 2.20 | 0.38 | 0.85 | 4.28 | -0.55 |
Acutaas Chemicals Limited specializes in manufacturing pharmaceutical intermediates and diversified chemicals, focusing on expanding into battery and semiconductor chemicals.
The company has reported a robust financial performance, with a 43% YoY increase in revenue and a 133.7% increase in PAT in Q3 FY26, highlighting its strong operational leverage and cost efficiencies.
Acutaas is strategically investing in new growth verticals like battery and semiconductor chemicals, with anticipation of significant revenue contributions by FY 2028, aimed at diversification and de-risking its business model.
The company’s recent inauguration of its Jhagadia plant marks its commitment to establishing a substantial presence in the battery chemicals domain, reflecting its proactive approach to future energy solutions.
With a focus on high-margin sectors like advanced pharmaceutical intermediates and substantial investment in R&D, Acutaas aims to strengthen its competitive edge and innovations across its product portfolio.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
16,507 Cr
High Risk
57.5
55.7
1.8
11.7
2,120.00
930.03
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Acutaas Chemicals Ltd (ACUTAAS) is currently trading at 2,016.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Acutaas Chemicals Limited specializes in manufacturing pharmaceutical intermediates and diversified chemicals, focusing on expanding into battery and semiconductor chemicals. The company has reported a robust financial performance, with a 43% YoY increase in revenue and a 133.7% increase in PAT in Q3 FY26, highlighting its strong operational leverage and cost efficiencies. Acutaas is strategically investing in new growth verticals like battery and semiconductor chemicals, with anticipation of significant revenue contributions by FY 2028, aimed at diversification and de-risking its business model. The company’s recent inauguration of its Jhagadia plant marks its commitment to establishing a substantial presence in the battery chemicals domain, reflecting its proactive approach to future energy solutions. With a focus on high-margin sectors like advanced pharmaceutical intermediates and substantial investment in R&D, Acutaas aims to strengthen its competitive edge and innovations across its product portfolio.
Over the past 52 weeks, Acutaas Chemicals Ltd has traded between a low of ₹930.03 and a high of ₹2,120.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Acutaas Chemicals Ltd has a market capitalization of approximately 16,507.26. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Acutaas Chemicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 57.52 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,507.26 Cr, Acutaas Chemicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Acutaas Chemicals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Acutaas Chemicals Ltd is 57.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 'ADD' rating is based on JSW Steel's strong volume growth visibility from capacity expansions, potential for margin recovery due to rising steel prices, and strategic deleveraging through the BPSL stake monetization.
The ₹10,000 crore scheme focuses on domestic production of biologics and biosimilars, which increases demand for the advanced pharmaceutical intermediates that make up 85% of Acutaas's revenue.
Bearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
